Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

06.12.22	Pfizer Seeks FDA Approval For Bivalent COVID-19 Vaccine In Kids Under 5 (RTTNews)
01.12.22	Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day (Businesswire)
01.12.22	Roivant Forms New Vant With Pfizer To Develop PF-06480605 For Inflammation Diseases (RTTNews)
01.12.22	Valneva, Pfizer Report 6-Month Antibody Persistence Data For Lyme Disease Vaccine Candidate (RTTNews)
28.11.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
16.11.22	Form 4 78003 (RSS)
11.11.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
09.11.22	Form 10-Q 78003 (RSS)
04.11.22	Pfizer, BioNTech Reveal Updated Data For Omicron BA.4/BA.5-Adapted Bivalent Booster (RTTNews)
03.11.22	Pfizer's Elranatamab Gets Breakthrough Therapy Designation From FDA For R/R Multiple Myeloma (RTTNews)
03.11.22	Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma (Businesswire)
01.11.22	Pfizer Reports Positive Top-Line Trial Data For Bivalent RSV Vaccine Candidate (RTTNews)
01.11.22	Pfizer Boosts FY22 Outlook As Q3 Results Top Estimates (RTTNews)
01.11.22	Pfizer Inc. Reveals Advance In Q3 Income (RTTNews)
01.11.22	PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK (Businesswire)
01.11.22	Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate (Businesswire)
01.11.22	Form 8-K 78003 (RSS)
28.10.22	GSK: EMA Validates ViiV Healthcare's MAA For Cabotegravir Long-acting Injectable For HIV Prevention (RTTNews)
28.10.22	ViiV Healthcare : EMA Validates MAA For Cabotegravir Long-acting Injectable For HIV Prevention (RTTNews)
21.10.22	Pfizer Likely To Hike U.S. COVID Vaccine Price (RTTNews)
20.10.22	Pfizer-BioNTech's COVID-19 Vaccine Recommended In EU For Children Under 5 Yrs (RTTNews)
18.10.22	Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022 (Businesswire)
13.10.22	Pfizer- BioNTech Early Study Data For Omicron BA.4/BA.5-Adapted Bivalent Booster Vaccine, Positive (RTTNews)
13.10.22	Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older (Businesswire)
12.10.22	Pfizer : FDA Grants Emergency Use Of Omicron Bivalent COVID-19 Vaccine Booster In Children (RTTNews)
12.10.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age (Businesswire)
05.10.22	Pfizer Completes Acquisition of Global Blood Therapeutics (Businesswire)
04.10.22	Pfizer Reports Positive Topline Results From Phase 3 TALZENNA Trial (RTTNews)
04.10.22	Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial (Businesswire)
03.10.22	Pfizer Completes Acquisition of Biohaven Pharmaceuticals (Businesswire)
26.09.22	Pfizer, BioNTech Apply For EUA In US Of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster In Kids (RTTNews)
26.09.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age (Businesswire)
22.09.22	Pfizer Declares Fourth-Quarter 2022 Dividend (Businesswire)
22.09.22	Pfizer To Supply 6 Mln Paxlovid Treatment Courses To Fight Covid-19 (RTTNews)
22.09.22	Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries (Businesswire)
20.09.22	Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts (Businesswire)
19.09.22	Pfizer Posts Positive Study Data In 20-Valent Pneumococcal Conjugate Vaccine In Infants In EU (RTTNews)
19.09.22	Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union (Businesswire)
16.09.22	Pfizer - BioNTech COVID-19 Vaccine Recommended For Full Approval In EU (RTTNews)
15.09.22	Pfizer Says Late-stage Study Of Pentavalent Meningococcal Vaccine Candidate Met Primary Goal (RTTNews)
15.09.22	Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents (Businesswire)
14.09.22	Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022 (Businesswire)
14.09.22	Pfizer Doses First Participants In Phase 3 Study Of MRNA-Based Influenza Vaccine (RTTNews)
14.09.22	Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine (Businesswire)
13.09.22	Pfizer To Provide Therapeutics For Strata PATH Trial - Quick Facts (RTTNews)
13.09.22	Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer (PR Newswire)
13.09.22	Pfizer And BioNTech Receive Positive CHMP Opinion For Omicron COVID-19 Vaccine Booster In EU (RTTNews)
12.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union (Businesswire)
09.09.22	Pfizer : FDA And EMA Accept Regulatory Submission For Ritlecitinib For Alopecia Areata (RTTNews)
09.09.22	FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

17:57		Börse Europa in Grün: STOXX 50 steigt schlussendlich
17:57		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
17:57		Dienstagshandel in London: Letztendlich Gewinne im FTSE 100
16:15		AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück
16:02		Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Verlust hätte ein Merck-Investment von vor einem Jahr eingefahren
16:02		S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr eingebracht
16:00		NYSE-Handel: Dow Jones beginnt Dienstagshandel mit Gewinnen

17:57

Börse Europa in Grün: STOXX 50 steigt schlussendlich

17:57

Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50

17:57

Dienstagshandel in London: Letztendlich Gewinne im FTSE 100

16:15

AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück

16:02

Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Verlust hätte ein Merck-Investment von vor einem Jahr eingefahren

16:02

S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr eingebracht